VERA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.51%, SMA50 -8.96%, SMA200 35.92%). The stock’s 14-day RSI is 45.0 (neutral), while the ATR of 2.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.44% below its high and over 128.55% above its low. Average 10-day trading volume of 943.45 thousand shares is below the 3-month average of 1.19 million, indicating normal recent market interest.

Vera Therapeutics, Inc. (NASDAQ:VERA) closed at $39.30 USD, losing -$1.12 (-2.77%) from the previous close of $40.42. The stock is currently mid-range between its 52-week high and low $18.53 and $56.05. With a market capitalization of about $2.75 billion, Vera Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 1.21 million shares, in line with its 52-week average. Headquartered in Brisbane, CA, Vera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marshall W. Fordyce, the company employs approximately 152 people and listed since May 14, 2021. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States.

Vera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.32. This means the shares are trading above this model’s fair value.

Vera Therapeutics, Inc. generated EPS of -$3.99 over the past year. Five-year average earnings growth is 4.49%. Wall Street analysts project EPS growth of 2.47% annually over the next five years. The latest quarter delivered EPS of -$1.26. The next quarter is forecast at -$1.28. Next year's EPS is expected at -$1.12. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $110.00 to $33.00. The high target offers 179.9% upside. The low target suggests -16.03% downside. The mean target is $73.23. This offers 86.34% upside. Vera Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 5.0%. The prior quarter beat by 46.34%. Over the last six quarters, Apple has recorded several small beats. These include 6.9% in August 08, 2024.

Vera Therapeutics, Inc. has 63.82 million shares outstanding. The public float is 42.92 million shares, elevated short interest at 15.31% of float. This equals 8.48 million shares. The short ratio is 5.0 days. Institutional investors hold 104.25% of the float. Insiders own 0.88%. COMMODORE CAPITAL LP holds 4.40 million shares, Sofinnova Venture Partners X, L.P. has 3.47 million shares and Carlyle Genesis UK LLC has 2.96 million shares. Over the past six months, insider transactions show net selling. They sold 82.35 thousand shares across 12 transactions.

Vera Therapeutics, Inc. trades at a P/E ratio of -8.45, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.19 trading at moderately above to book value. The P/FCF stands at -11.43, also above market averages.

Our AI price prediction model suggests that Vera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.8%, with price expected at $38.20 by March 17, 2026, within a range of $36.79 to $39.54 3-Month Outlook: Projected rise of 45.6%, reaching $57.22 by June 01, 2026, with a range of $55.66 to $58.98. 1-Year Outlook: Projected gain of 21.04%, with price at $47.57 by March 03, 2027, within a range of $44.14 to $51.66.

Vera Therapeutics, Inc. (NASDAQ:VERA) shares are down -11.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $58.06, suggesting 47.74% upside. Our AI forecast model points to short-term weakness (-2.8% over two weeks), a medium-term rise (45.6% over three months), and a longer-term gain (21.04% over one year), with expected trading ranges indicating moderate volatility.